Fonadelpar

DB16169InvestigationalSmall molecule

Fonadelpar is under investigation in clinical trial NCT03527212 (A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease).

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor delta
Curator reviewed
Formula / weight: C₂₅H₂₃F₃N₂O₄S · 504.52 g/mol (avg)
Code names: NPS-005 · SJP-0035

Resolves to

Compound

UNIIFK5ZAD810ZCAS515138-06-4ChEMBLCHEMBL3545186

Structure

InChIKeyWWKYLBGQYALEDL-UHFFFAOYSA-NSMILESCC(C)C1=C(CCC2=NOC3=CC(OCC(O)=O)=C(C)C=C23)SC(=N1)C1=CC=C(C=C1)C(F)(F)F

Targets

Q03181PPARD

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fonadelpar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account